Although virtually no one in the urban bubble where biopharmaceutical companies reside expected it to happen, Donald Trump won. So, now what?
Before there are new therapies to set a firm apart, there is a far more fundamental need that competitiveness will ultimately hinge on: high-quality, diversified, annotated human biospecimens.
Biogen reported Q2 profit that blew past Wall Street estimates; Chief Executive George Scangos will step down in the coming months once a successor is found.
Abbott Laboratories reported better-than-expected quarterly sales and profit with strong sales in its medical device business.
Bristol-Myers Squibb Co said the U.S. Food and Drug Administration had approved the expanded use of its cancer drug, Opdivo, to treat an additional form of advanced skin cancer. Opdivo, […]
November 24, 2015By Mark Terry, BioSpace.com Breaking News Staff Now that the Pfizer (PFE)-Allergan (AGN) merger is official, the company and analysts are looking at details about the merged […]
November 17, 2015By Mark Terry, BioSpace.com Breaking News Staff Boston-based Vertex Pharmaceuticals (VRTX) presents an unusual business model one that has been the focus of a Harvard case study. […]
AbbVie Inc (ABBV.N) reported higher quarterly sales and net income on Friday and forecast double-digit growth of earnings per share through 2020, putting the drugmaker in line to beat Wall […]
Amgen Inc (AMGN.O) on Wednesday reported much higher-than-expected third-quarter profit, helped by a 30-percent spike in revenue from the rheumatoid arthritis drug Enbrel due to price increases and inventory stocking. […]
U.S. health regulators on Tuesday approved Amgen Inc’s novel cancer immunotherapy for injection into melanoma lesions and lymph nodes of patients with the deadliest form of skin cancer that returns […]
